Advances in cardioprotective strategies: bridging traditional pharmacotherapy and regenerative medicine

Гладких, Ф.В.; Матвєєнко, М.С.; Лядова, Т.І.; Карафуліді, О.В.; Коморовський, Р.Р.

Головна сторінка
→
PUBLICATIONS
→
PUBLICATIONS
→
Перегляд матеріалів

dc.contributor.author	Гладких, Ф.В.
dc.contributor.author	Матвєєнко, М.С.
dc.contributor.author	Лядова, Т.І.
dc.contributor.author	Карафуліді, О.В.
dc.contributor.author	Коморовський, Р.Р.
dc.date.accessioned	2025-07-01T13:33:36Z
dc.date.available	2025-07-01T13:33:36Z
dc.date.issued	2025-06-30
dc.identifier.citation	Hladkykh FV, Liadova TI, Matvieienko MS, Karafulidi OV, Komorovsky RR. Advances in cardioprotective strategies: bridging traditional pharmacotherapy and regenerative medicine. Scripta Medica. 2025;56(3):521–35. DOI: https://10.5937/scriptamed56-58719. Режим доступу: https://aseestant.ceon.rs/index.php/scriptamed/article/view/58719/28168	uk_UA
dc.identifier.uri	https://10.5937/scriptamed56-58719
dc.identifier.uri	https://aseestant.ceon.rs/index.php/scriptamed/article/view/58719/28168
dc.identifier.uri	https://pubmed.com.ua/xmlui/handle/123456789/1161
dc.description	Cardiovascular diseases (CVDs) remain the leading global cause of death and disability, underscoring the need for improved therapies. Key emerging strategies include pharmacological cardioprotection, cell-based therapies and the use of exosomes as therapeutic agents and biomarkers. Aim of this study was to characterise contemporary approaches to cardioprotection in CVDs, including pharmacological agents, cell-based therapies and exosome-based strategies, based on an analysis of evidence-based data. A systematic literature search was performed using databases including PubMed, Clinical Key (Elsevier), Cochrane Library, eBook Business Collection and Google Scholar. Keywords included cardioprotection, exosomes, cell-based therapies and pharmacological approaches. Article selection followed evidence-based medicine principles and the PRISMA guidelines. Current cardioprotective strategies include both traditional pharmacological agents, such as β-blockers, calcium channel blockers, ACE inhibitors, statins and nitrates, as well as innovative approaches like cell-based therapies and the use of exosomes. The advantages and limitations of cell therapy were analysed, including challenges related to low cell survival, failure of differentiation and the risk of arrhythmias. The role of exosomes and microvesicles as promising markers of cardiovascular injury and potential therapeutic agents was also explored. Combining pharmacological, cell-based and exosome-based strategies offers new prospects for cardioprotection in CVDs. Further research is required to optimise the clinical use of cell therapies and to confirm the efficacy of exosome-based interventions.	uk_UA
dc.description.abstract	Hladkykh FV, Liadova TI, Matvieienko MS, Karafulidi OV, Komorovsky RR. Advances in cardioprotective strategies: bridging traditional pharmacotherapy and regenerative medicine. Scripta Medica. 2025;56(3):521–35. DOI: https://10.5937/scriptamed56-58719. Режим доступу: https://aseestant.ceon.rs/index.php/scriptamed/article/view/58719/28168	uk_UA
dc.language.iso	uk	uk_UA
dc.publisher	Scripta Medica. 2025;56(3):521–35.	uk_UA
dc.title	Advances in cardioprotective strategies: bridging traditional pharmacotherapy and regenerative medicine	uk_UA
dc.title.alternative	Advances in cardioprotective strategies: bridging traditional pharmacotherapy and regenerative medicine	uk_UA
dc.type	Article	uk_UA